Harrow vs Xeris Biopharma Holdings
Harrow and Xeris Biopharma Holdings are similar in size: $272m and $292m of revenue in their latest fiscal years. Xeris Biopharma Holdings grew faster (43.7% against 36.4%). Xeris Biopharma Holdings kept more of each dollar of sales as profit: a net margin of 0.2% against -1.9%.
| Latest fiscal year | HarrowHROW, 2025 | Xeris Biopharma HoldingsXERS, 2025 |
|---|---|---|
| Revenue | $272m | $292m |
| Revenue growth | 36.4% | 43.7% |
| Net income | −$5.1m | $554,000 |
| Operating margin | — | 8.5% |
| Net margin | -1.9% | 0.2% |
| Return on equity | -8.4% | — |
| Free cash flow | $43.0m | $28.6m |
| Cash | $72.9m | $111m |
| Total debt | $250m | $234m |
| Debt to equity | — | 1706.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 435 |
| Market value | $1.06bn | $1.81bn |
| Price vs our value range | Above our value range | — |
| Moat score | 26 (Weak) | 15 (Weak) |
| Insider trades, 12 months | 4 buys, 7 sales | 0 buys, 33 sales |